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Background: To investigate the long-term effects on immunity of an inactivated enterovirus 71 (EV71) vaccine and
its protective efficacy.
Methods: A sub-cohort of 1,100 volunteers from Guangxi Province in China was eligible for enrolment and randomly
administered either the EV71 vaccine or a placebo on days 0 and 28 in a phase III clinical trial and then observed for
the following 2 years with approval by an independent ethics committee of Guangxi Zhuang Autonomous Region,
China. Serum samples from the 350 participants who provided a full series of blood samples (at all the sampling
points) within the 2-year period were collected. Vaccine-induced immune effects, including the neutralizing
antibody titres and cross-protection against different genotypes of EV71, were examined. This study also
evaluated the protective efficacy of this vaccine based upon clinical diagnosis.
Results: This sub-cohort showed a >60 % drop-out rate over 2 years. The seroconversion rates among the 161
immunized subjects remained >95 % at the end of study. The geometric mean titres of neutralizing antibodies
(anti-genotype C4) 360 days after vaccination in 350 subjects were 81.0 (subjects aged 6–11 months), 98.4 (12–23
months), 95.0 (24–35 months), and 81.8 (36–71 months). These titres subsequently increased to 423.1, 659.0,
545.0, and 321.9, respectively, at 540 days post-immunization (d.p.i.), and similar levels were maintained at 720
d.p.i. Higher IFN-γ/IL-4-specific responses to the C4 genotype of EV71 and cross-neutralization reactivity against
major EV71 genotype strains were observed in the vaccine group compared to those in the placebo group. Five
EV71-infected subjects were observed in the placebo-treated control group and none in the vaccine-immunized
group in per-protocol analysis.
Conclusion: These results are consistent with the induction of dynamic immune responses and protective
efficacy of the vaccine against most circulating EV71 strains.
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Hand, foot, and mouth disease (HFMD) has recently
emerged in the Asian-Pacific region as the most severe
epidemic disease affecting children [1, 2]. The effective
prevention and control of HFMD epidemics is widely rec-
ognized as an essential public health issue [3, 4]. Entero-
virus 71 (EV71) and coxsackievirus A16 (CA16) are the
two major pathogens causing HFMD. Of these two vi-
ruses, EV71 infection is associated with a higher death rate
and is primarily responsible for fatalities [5–7]. Attempts
to develop inactivated EV71 vaccines have made signifi-
cant progress over a short period [8–10]. In a published
report of a 1-year phase III clinical trial, an inactivated
EV71 vaccine derived from a C4 genotype strain (the
predominant strain circulating on the Chinese mainland)
displayed adequate safety, immunogenicity, and efficacy,
showing an efficacy of 97.4 % and geometric mean titres
(GMTs) of 224.4 and 118.0 at 56 and 180 days post-
immunization (d.p.i.), respectively [8]. However, the
long-term effects of a vaccine on immunity (specifically,
its cross-protection against circulating strains of various
genotypes) are generally considered critical characteristics
for its licensing and clinical application.
Herein, we report the results of a continued evaluation
of the immunogenicity, immune memory effects, and ef-
ficacy of this EV71 vaccine in a sub-cohort of subjects.
Initially, 1,100 subjects were selected for the random ad-
ministration of either the vaccine or a placebo, and 350
subjects provided a complete series of blood samples
within the 2-year study period. In the present study, we
performed a cross-neutralization assay with nine individual
EV71 strains of genotypes A, B (B3–B5), and C (C1–C5),
using 160 serum samples obtained from the 350 subjects
from the immunized and placebo groups, in a 1:1 ratio.
The results show the efficacy of the immune response in-
duced by the inactivated EV71 vaccine and provide sub-
stantial data on the potential utility of this vaccine.Methods
Vaccine and vaccination
The inactivated EV71 vaccine was developed in a good
manufacturing practice-compliant facility at the Institute
of Medical Biology, Chinese Academy of Medical Sciences,
and was tested at the National Institutes for Food and
Drug Control before this study. The vaccine was prepared
from the EV71 FY-23K-B strain of sub-genotype C4,
cultured in a human diploid cell line (KMB17) for pro-
liferation, and then purified and inactivated. Each dose
of the vaccine contained 100 U of inactivated EV71
viral antigen adsorbed onto 0.5 mg of aluminum hy-
droxide, suspended in 0.5 mL of buffered saline. Both the
vaccine and placebo were administered intramuscularly at
0 and 28 days.Subjects and study design
The primary outcome of this trial was the determination
of the efficacy of an inactivated EV71 vaccine, and the
secondary outcome was the evaluation of the long-term
immune persistence of this vaccine over a 2-year obser-
vation period. The study was conceived and performed
with a randomized, double-blind, placebo-controlled co-
hort and registered at Clinicaltrials.gov as NCT01569581
[8]. The study was proposed by the Centres for Disease
Control and Prevention of Guangxi Province in association
with a professional statistics group from the Fourth Mili-
tary Medical University, and was approved by the China
Food and Drug Administration and an independent ethics
committee of Guangxi Zhuang Autonomous Region, China
(Additional file 1). A subset of 1,100 children, whose legal
guardian provided written informed consent (Additional
file 1), from the 12,000 subjects of the phase III trial under-
taken in the Guilin region of Guangxi Province, China,
were eligible for enrolment and randomly selected based
on the inclusion criteria for participation (see Methods in
the Additional file 1). The subjects were grouped according
to age: 6–11 months (n = 350), 12–23 months (n = 350),
24–35 months (n = 300), and 36–71 months (n = 100).
The subjects within each age group were randomly
assigned to receive either the vaccine or the placebo, in
a ratio of 1:1. To measure the immune responses, blood
samples were collected from each available subject at
baseline and at 56, 180, 360, 540, and 720 d.p.i., admin-
istered between March and April 2012. A suspected
case of HFMD was defined as having a febrile illness
(>37.5 °C) accompanied by a papular/vesicular rash
with the characteristic distribution on the oral mucosa
and limb extremities (see Methods in the Additional file 1).
A case of EV71 HFMD was defined as a suspected case of
HFMD in whom EV71 was detected with a throat swab or
stool specimen, using quantitative reverse transcription–
polymerase chain reaction (qRT–PCR). A case of severe
EV71 HFMD was defined as a suspected case of HFMD
with neurological, respiratory, or circulatory complications
based on the HFMD diagnostic criteria of the Ministry of
Health of China [11]. To integrate the identification of ac-
tive cases across the region, a healthcare center-based sur-
veillance system was established in each county to detect
suspected cases of HFMD. SimoonRecord, an independ-
ent contract research organization, assessed all clinical
data at the end of each year. The surveillance method and
the processing of suspected cases have been described
elsewhere [8]. Because the vaccine is not yet licensed, the
trial cohort was monitored under the same disease sur-
veillance system after unblinding.
Measurement of the persistent immune response
Serum samples from the 350 participants who provided
a full series of blood samples (at all the sampling points)
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were investigated for the 2-year study according to per-
protocol analysis. The samples were assayed for EV71-
specific neutralizing antibodies with a micro-neutralization
assay on Vero cells grown in 96-well plates and a standard
viral strain (C4) provided by the National Institutes for
Food and Drug Control [8]. Susceptible participants, who
showed a level of neutralizing antibodies against the C4
genotype of EV71 of <1:8 (the threshold of detection) be-
fore immunization, were assigned a value of 1:4.
Overall, 160 individuals (40 individuals in each age
group: 20 individuals in the vaccine group and 20 in the
placebo group, all of whom provided a full series of
blood samples within the 2-year study period) were ran-
domly selected using the RAND function in the EXCEL
software (Microsoft, Redmond, WA, USA). Their serum
samples were collected at 0, 56, and 360 d.p.i. for the
cross-neutralization assay. Nine strains of the EV71 virus
(genotypes A, B3, B4, B5, C1, C2, C3, C4, and C5) were
used in this assay (Additional file 1). Of these strains, all
but genotype A were isolated from epidemics occurring
in various areas within the Asian-Pacific region [12–15].
The viral strains, grown on Vero cell monolayers, were
harvested after the typical cytopathic effect was ob-
served, and the titres were determined. Three hundred
cell culture infectious doses of all the viruses were used
for the neutralization test.
A total of 40 blood samples (10 samples from each age
group: five samples from the vaccine group and five
samples from the placebo group) were selected randomly
from the 350 subjects who had provided a complete series
of blood samples within the 2-year study period. The
serum samples collected at 720 d.p.i. were used in
interferon-γ (IFN-γ) and interleukin-4 (IL-4) enzyme-
linked immunospot (ELISPOT) assays (Mabtech AB,
Stockholm, Sweden). The ELISPOT assays were performed
as previously described. Briefly, a 96-well polyvinylidene-
difluoride-backed plate was pre-coated with anti-IFN-γ or
anti-IL-4 monoclonal antibody, incubated overnight, and
blocked for 1 h at 37 °C. The wells containing a predeter-
mined density of peripheral blood mononuclear cells
(PBMCs) and a stimulatory peptide (10 mg/mL; amino
acid sequence: STAETTLDSFF) [16] were incubated at
37 °C for another 24 h. The cells were then removed
and the colors were developed according to the manu-
facturer’s instructions. The colored spots were counted
with an automated ELISPOT reader (Cellular Technology
Limited, OH, USA). The spot-forming cells were EV71
epitope-specific IFN-γ-producing T cells.
Statistical analysis
The analysis of this observational study was begun in
March 2012, and the follow-up by professional statisticians
from the Fourth Military Medical University is ongoing.Based on the fact that a 0.7 % HFMD morbidity was ob-
served in children aged 6–72 months in Guangxi Province,
China, in 2009–2011 [8, 17, 18], and that 55–72 % of
HFMD cases were identified as being infected by EV71 [8,
17, 18], 6,000 subjects per arm were required to detect any
difference in vaccine efficacy between the vaccine and
placebo groups with a statistical power of 90 % and a
two-tailed alpha of 0.05. Because a 20 % dropout rate
was considered probable within the 12 months after
vaccination in the phase III trial and at least 2 years
were required to obtain adequate data from which to
estimate the long-term efficacy of the seroprotection in-
duced by the EV71 vaccine, we specified 1,100 children as
the recruitment target for this study. This sample size rep-
resents approximately 10 % of the 12,000 total subjects in
the phase III trial, and comprised 550 subjects per arm, in
a ratio of 1:1 for the vaccine- and placebo-treated groups.
A difference was detected in the neutralization antibodies
induced in the vaccine and placebo groups, with a statis-
tical power of 90 % and a two-tailed alpha of 0.05. The
Kaplan–Meier method was used to compare the vaccine
efficacy, and the Mantel–Haenszel χ2 method was used to
assess the differences in the two groups. Student’s t-test or
the Mann–Whitney U test (when the data were not nor-
mally distributed) was used to assess the dimensional out-
comes, and the χ2 test or Fisher’s exact test (when the
data were sparse) was used to assess the dichotomous
outcomes. Both types of outcomes were evaluated in a
two-tailed manner. In the statistical analysis of the anti-
body titres, the values were converted to logarithms to
facilitate the assessment of the GMTs. The SAS software
version 9.1 (SAS Institute) was used for all statistical
analyses.
Results and Discussion
Clinical phase III trials have shown that inactivated EV71
vaccines are effective in the control and prevention of
HFMD caused by EV71 infection in child populations
[8–10]. The present study was based on four individual
age groups in a sub-cohort comprising 1,100 subjects
who had been included in a previous clinical trial [8].
The major vaccinated cohorts in these groups were at a
susceptible age for the development of HFMD, according
to epidemiological studies [19], because understanding the
dynamic profiles of anti-EV71 antibodies in children
vaccinated during this period of life is essential to prevent
disease development.
In the present study, 1,100 participants in the four age
groups were allocated to either the experimental or con-
trol groups, in a 1:1 ratio (Additional file 1: Table S1).
According to the primary design, the phase III trial was
initiated in March 2012 and ended after a 1-year follow-
up period. However, a long-term experiment using this
sub-cohort was continued for 2 years. Throughout the
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reason, were 72.0 %, 67.6 %, 68.3 %, and 56.0 % in the
6–11 month, 12–23 month, 24–35 month, and 36–71
month age groups, respectively (Fig. 1). The high drop-
out rates, which included some individuals who moved
away and some who refused to provide samples (Fig. 1),
predominantly reflected the relocation of families, which
has been occurring more frequently in rural and urban
areas in recent years. After drop-out, 350 subjects
remained in this sub-cohort (161 participants in the im-
munized group and 189 in the placebo group), and par-
ticipated in an immunological study at all 56, 180, 360,
540 and 720 d.p.i. time points according to per-protocol
analysis (Fig. 1).
The levels of neutralizing antibodies (against genotype
C4 virus) in the sera of the vaccinated subjects 56 d.p.i.
were 141.9 (95 % confidence interval [CI], 102.0–197.3)Fig. 1 Schematic representation of the phase III clinical trial of an inactivat
were assessed for a phase III clinical trial and 12,000 eligible volunteers were r
samples of 1,100 individuals were collected at 0, 56, 180, 360, 540, and 720 da
antibodies. The follow-up rates (%) are indicated for each time pointin the 6–11 months group, 224.0 (95 % CI, 162.1–309.6)
in the 12–23 month age group, 204.4 (95 % CI, 128.9–
324.2) in the 24–35 month age group, and 258.4 (95 %
CI, 109.4–610.3) in the 36–71 month age group, whereas
those in the sera of the placebo control subjects were
4.1 (95 % CI, 3.9–4.3 ), 4.7 (95 % CI, 3.7–5.8 ), 10.8
(95 % CI, 6.3–18.5), and 32.1 (95 % CI, 12.8–80.5), re-
spectively (Fig. 2). These clear differences suggest the
effective immunogenicity of the vaccine. However, the
antibody titres of the vaccinated children subsequently
decreased to 71.2 (95 % CI, 54.2–93.5), 96.2 (95 % CI,
66.2–139.8), 110.8 (95 % CI, 70.6–173.8), and 138.5
(95 % CI, 63.0–304.1), respectively, at 180 d.p.i., and simi-
lar levels were observed at 360 d.p.i. (Fig. 2). This probably
reflects the normal dynamic decay of the immune re-
sponses induced by viral antigens [20–22]. Interestingly,
the antibody levels increased to 423.1 (95 % CI, 276.2–ed enterovirus 71 vaccine. In total, 14,445 children, aged 6–71 months,
andomly assigned to receive the vaccine or a placebo [8]. The blood
ys after immunization to evaluate the production of anti-EV71 neutralizing
Fig. 2 Dynamic profiles of the antibody levels during a 2-year follow-up period in 350 children immunized with the vaccine. Blood samples from
350 participants, who provide a full series of blood samples within the 2-year follow-up period, were collected to evaluate the production of anti-
EV71 neutralizing antibodies. These children were 6–11 months old (a) (48 individuals in the vaccine group and 50 in the placebo group), 12–23
months old (b) (50 individuals in the vaccine group and 63 in the placebo group), 24–35 months old (c) (43 individuals in the vaccine group and
52 in the placebo group), and 36–71 months old (d) (20 individuals in the vaccine group and 24 in the placebo group). The geometric mean titres are
shown above the bar. The bar indicates the 95 % confidence interval
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368.2–860.8), and 321.9 (95 % CI, 139.5–742.7), re-
spectively, at 540 d.p.i. and to 443.4 (95 % CI, 274.2–
717.0), 402.4 (95 % CI, 249.5– 648.9), 545.0 (95 % CI,
344.7–861.4), and 202.7 (95 % CI, 88.4–465.0), respect-
ively, at 720 d.p.i. The antibody titres of the placebo
control subjects also increased in the older age groups
(Fig. 2c,d), but with only slight variations observed in
younger age groups (Fig. 2a,b). The GMTs of the pla-
cebo subjects were 97.3 in the 24–35 month age group
and 119.70 in the 36–71 month age group at 720 d.p.i.,
considerably higher than those in the 6–11 (17.07) and
12–23 (32.63) month age groups (Fig. 2). These results
suggest that older children more easily contract the cir-
culating virus than younger ones [23] (Fig. 2). Strik-
ingly, the serum conversion rates in the children of
all age groups observed at different time points were
typically greater than 95 % in the immunized cohort
(Table 1). These data suggest that higher serum anti-
body conversion rates and neutralizing antibody GMTswith protective significance were maintained in the cohort
immunized with the vaccine 2 years earlier. This demon-
strates the efficacy of this vaccine and the enhanced effect
of the antibody response in immunized individuals, which
might have been induced by naturally circulating virus, as
previously described [24–28].
The capacity to elicit immune memory in children is
also an important indicator of the clinical utility of a
vaccine [29]. Previous animal experiments and phase II
trials primarily measured the effective immune memory,
based on the IFN-γ-specific ELISPOT response of PBMCs
to stimulation with EV71 antigen in infant populations
within 2 months of immunization with two doses of an
inactivated EV71 vaccine [30, 31]. To evaluate the varia-
tions in the immune memory elicited in the immunized
population over an extended period of time, specific anti-
IFN-γ and IL-4 ELISPOT assays were performed on
PBMCs collected at 720 d.p.i. from 40 (10 from each age
group, with five from the immunized group and five from
the placebo group) of the 350 subjects to determine the
Table 1 Serum conversion rates in children immunized with
the EV71 vaccine who provided a full series of blood samples





Vaccineb Placebob P value
6–11 0 0/48 (0.0) 1/50 (2.0) 1.000
56 48/48 (100.0) 1/50 (2.0) <0.0001
180 47/48 (97.9) 8/50 (16.0) <0.0001
360 47/48 (97.9) 9/50 (18.0) <0.0001
540 47/48 (97.9) 14/50 (28.0) <0.0001
720 48/48 (100.0) 15/50 (30.0) <0.0001
12–23 0 2/50 (4.0) 2/63 (3.2) 1.000
56 50/50 (100.0) 2/63 (3.2) <0.0001
180 50/50 (100.0) 18/63 (28.6) <0.0001
360 50/50 (100.0) 19/63 (30.2) <0.0001
540 50/50 (100.0) 22/63 (34.9) <0.0001
720 48/50 (96.0) 27/63 (42.9) <0.0001
24–35 0 5/43 (11.6) 12/52 (23.1) 0.184
56 43/43 (100.0) 12/52 (23.1) <0.0001
180 43/43(100.0) 29/52 (55.8) <0.0001
360 42/43 (97.4) 31/52 (59.6) <0.0001
540 43/43 (100.0) 31/52 (59.6) <0.0001
720 43/43 (100.0) 35/52 (67.3) <0.0001
36–71 0 5/20 (25.0) 13/24 (54.2) 0.047
56 20/20 (100.0) 13/24 (54.2) <0.0001
180 20/20 (100.0) 19/24 (79.2) 0.031
360 20/20 (100.0) 19/24 (79.2) 0.031
540 20/20 (100.0) 18/24 (75.0) 0.016
720 19/20 (95.0) 18/24 (75.0) 0.071
Total 0 12/161 (7.5) 28/189 (14.8) 0.028
56 161/161 (100.0) 28/189 (14.8) <0.0001
180 160/161 (99.4) 74/189 (39.2) <0.0001
360 159/161 (98.8) 78/189 (41.3) <0.0001
540 160/161 (99.4) 85/189 (45.0) <0.0001
720 158/161 (98.1) 95/189 (50.3) <0.0001
aNeutralization antibody titre ≥1:8.
bPositive rate – Number (%)
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a synthesized VP1 peptide. The results showed signifi-
cant IFN-γ-specific ELISPOT responses to EV71 antigen
stimulation in the immunized children aged 6–11 months,
12–23 months, and 36–71 months (Fig. 3). The IL-4-
specific ELISPOT responses in these groups were also sig-
nificantly greater than those in the placebo control groups
(Fig. 3). However, the IFN-γ- and IL-4-specific responses
in the children aged 36–71 months were unexpectedly
lower than those in the other immunized groups, probably
reflecting the limited sample size (only five samples from
each group). Therefore, these findings require furtherinvestigation. Notably, in addition to the unexpected re-
sponses in the immunized group aged 24–35 months, an
enhanced IFN-γ response was observed in the placebo
control group, induced by an unidentified cause (Fig. 3c).
Although further clarification of these unexpected events
is required, these data suggest the maintenance of an im-
mune memory response and the induction of an antibody
response by the vaccine, which might have been affected
by virus circulating in the environment, through an as-
yet-unknown pathway [32].
These results are consistent with the clinical protective
efficacy of this vaccine. The cumulative clinical cases in
350 participants included five EV71-infected subjects (in
the placebo group) (Fig. 4a), four CA16-infected subjects
(one in the vaccine group and three in the placebo group),
and nine subjects infected with other enteroviruses
(three in the vaccine group and six in the placebo group;
Fig. 4b,c). Including the five described above, totally 15
EV71-infected cases (all in placebo group) were ob-
served in 1,100 subjects, along with 11 CA16-infected
cases (three in vaccine and eight in placebo) and 29
other enterovirus-infected cases (12 in vaccine and 17
in placebo; Additional file 1: Figure S1). These cases
were identified with clinical diagnoses and etiological
RT–PCR analyses.
These clinical data on the protective effects of the vaccine
and our consistent immunological observations, including
neutralizing antibody and immune memory responses, col-
lectively demonstrate the effective and sustainable im-
munogenicity of this vaccine, consistent with the results of
our previous clinical trial [8]. Epidemiological studies have
shown that the individual circulating EV71 viral strains, in-
cluding more than 10 genotypes and sub-genotypes, display
a great variety of distinctive characteristics in different
geographic regions and over different time periods [33, 34].
Recent EV71 candidate vaccines have typically been devel-
oped based on the C4 genotype strain circulating through-
out mainland China [8–10], but it is unclear whether
inactivated candidate vaccines induce immunity with equal
efficacy against infections by strains of other genotypes.
We randomly selected 160 individuals (40 individuals from
each age group: 20 individuals in the vaccine group and
20 in the placebo group) and collected serum samples
at 0, 56, and 360 d.p.i. The samples were used in a cross-
neutralization assay with nine EV71 strains belonging to
genotypes A, B, and C. Of the strains used (A, B3, B4,
B5, C1, C2, C3, C4, and C5), all but genotype A were
predominant strains circulating across broad regions of
Asian-Pacific countries [12–15]. The results showed re-
markable cross-neutralizing reactivity to the majority of
these strains, with a tendency towards a more dynamic
antibody response in the cohorts immunized with this
vaccine than in the placebo-treated controls (Fig. 5). Inter-
estingly, all of the sera exhibited similar low neutralizing
Fig. 3 EV71 antigen stimulated specific IFN-γ and IL-4 responses in peripheral blood mononuclear cells from volunteers immunized with either
the vaccine or placebo. Blood samples from 40 participants from among the 350 subjects who provided a full series of blood samples within the
2-year follow-up period were obtained at 720 days after immunization to evaluate IFN-γ and IL-4 production. These children were 6–11 months
old (a) (five individuals in the vaccine group and five in the placebo group), 12–23 months old (b) (five individuals in the vaccine group and five
in the placebo group), 24–35 months old (c) (five individuals in the vaccine group and five in the placebo group), and 36–71 months old (d) (five
individuals in the vaccine group and five in the placebo group). The mean levels of cytokines are shown above the bar
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ing titres were higher than the positive control titre of 1:8
(Fig. 5); the reason for this result is largely unknown.
However, the body of evidence presented here and the
data of Zhang, Huang, and Mao [35–37] are sufficient to
conclude that an inactivated EV71 vaccine derived from
one genotype strain could be effectively used to induce ad-
equate protective immunity against infection by most of
the predominant circulating EV71 strains.
The present study, which examined a sub-cohort of
the population used for a clinical phase III trial of this
new viral vaccine, did not include all the subjects in the
trial, and importantly, was unblinded at 1 year after vac-
cination, according to the design requirements. However,
this unblinding did not affect the reliability of neutraliz-
ing antibody results for these subjects. This study also
included a comparison of the protective efficacy of the
vaccine in the immunized and placebo-treated groups.
The observation of a lower neutralizing capacity against
a genotype C1 strain that has been detected sporadicallyin Asian populations [38] was perplexing, especially as
the amino acid sequence of the VP1 protein of this strain
is similar to that of the other genotypes. The enhanced
IFN-γ ELISPOT response to stimulation with an EV71
antigen in the PBMCs from 2- to 3-year-old children in
the placebo control group relative to the response in the
vaccinated group remains unexplained. The 2-year ob-
servation period in the present study was too short since
more information about the immunogenicity of this new
vaccine is required.
Conclusions
This study provides data on the systemic immune re-
sponse induced by this EV71 vaccine, including the clin-
ical protective efficacy against EV71 infection, the
specific immune memory, and the neutralizing antibody
response, particularly with respect to initial interactions
with various pandemic EV71 strains. Therefore, our re-
sults support the use of this vaccine as an immuno-
logical strategy for children in the near future.
Fig. 4 Cumulative cases of hand, foot, and mouth disease (HFMD) reported in 350 participants. A total of 350 participants (161 individuals in the
vaccine group and 189 in the placebo group), who provided a full series of blood samples (at all the sampling points) within the 2-year study period,
were observed during the surveillance period. The cumulative curves for the cases of HFMD induced by enterovirus 71 (EV71), coxsackievirus A16
(CA16), and other enteroviruses were estimated as a percentage among these participants with Kaplan–Meier survival curves during the period from
the receipt of the first dose until 24 months thereafter. The inset shows the same data on an enlarged y-axis. Differences in the distributions of cases
of HFMD among the individuals who received the placebo and those who received the vaccine were evaluated with a log-rank test. a Cumulative
curve for the cases of HFMD induced by EV71. b Cumulative curve for the cases of HFMD induced by CA16. c Cumulative curve for the cases of HFMD
induced by other enteroviruses
Fig. 5 Cross-neutralizing reactivity of different viral strains of various genotypes to sera taken from 160 individuals. Serum samples from 160
individuals (40 individuals in each age group; 20 individuals in the vaccine group and 20 in the placebo group), from among the 350 subjects
who provided a full series of blood samples within the 2-year study period, were collected at 0, 56, and 360 days post-immunization for a cross-
neutralization assay with different genotypes of enterovirus 71: A, B (B3–B5), and C (C1–C5). The geometric mean titres are shown above the bar.
The bar indicates the 95 % confidence interval
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Additional file 1: Detailed information for Method section (including
the description of virus strains, summary of long-term phase III clinical
trail, the ethics and protocol of long–term observation of phase III
clinical trial, the consent form and additional supplemental data.
Figure S1 legendA total of 1,100 participants, receiving either the
vaccine or placebo, were observed during the surveillance period. The
cumulative curves for the cases of HFMD induced by enterovirus 71
(EV71), coxsackievirus A16 (CA16), and other enteroviruses were
estimated as a percentage among these participants with Kaplan–Meier
survival curves during the period from the receipt of the first dose until
24 months thereafter. The inset shows the same data on an enlarged
y-axis. Differences in the distributions of cases of HFMD among the
individuals who received the placebo and those who received the
vaccine were evaluated with a log-rank test. (A) Cumulative curve for
the cases of HFMD induced by EV71. (B) Cumulative curve for the cases
of HFMD induced by CA16. (C) Cumulative curve for the cases of HFMD
induced by other enteroviruses. (PDF 2302 kb)
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